Image may be NSFW.
Clik here to view.
Clik here to view.
- The controversy regarding IV tPA treatment for stroke cannot be resolved with the current evidence
- Recent FDA labeling changes and potential conflicts between the ACEP and the AHA/ASA policy recommendations have only fueled the tPA controversy
- Advanced imaging practices will likely lead to improvement in determining which patients are likely to benefit or be harmed from IV tPA treatment
- You are much more likely to be sued for not treating a perceived IV tPA eligible patient than for treating someone who sustains an ICH after tPA treatment
